Previous Close | 46.4 |
1-Year Change | 19.46% |
6-Months Change | 12.95% |
3-Months Change | -17.67% |
Moving Avg (50d) | 53.602 |
Moving Avg (200d) | 48.111 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.35B |
Beta (3-Years) | 1.09 |
Revenue Growth (ttm) | 19.46% |
Net Profit Margin (ttm) | -154.87% |
Return On Assets (ttm) | -51.31% |
EPS (ttm) | -8.97 |
PE Ratio (ttm) | -5.17 |
Dividend Yield | % |
Asset Description: | Ultragenyx Pharmaceutical Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-20 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
45.472 | 44.08 | 43.152 | 41.76 | 39.44 | 37.12 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Ultragenyx is an American biopharmaceutical company involved in the Research and Development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone,... Wikipedia